773873-50-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Hydroxy-3-trifluoromethoxy-benzoic acid is used as an anti-inflammatory and anti-thrombotic agent for the treatment and prevention of cardiovascular diseases, such as heart attacks and strokes. It inhibits platelet aggregation and reduces inflammation, thereby lowering the risk of these conditions.
Used in Cardiovascular Applications:
2-Hydroxy-3-trifluoromethoxy-benzoic acid is used as a therapeutic agent for cardiovascular diseases, where it helps in preventing heart attacks and strokes by inhibiting platelet aggregation and reducing inflammation.
Used in Anti-cancer Research:
2-Hydroxy-3-trifluoromethoxy-benzoic acid is being investigated for its potential anti-cancer properties. Its ability to inhibit COX enzymes and reduce inflammation may contribute to its potential as a cancer treatment, although further research is needed to fully understand its mechanisms of action and efficacy in this context.

InChI:InChI=1/C8H5F3O4/c9-8(10,11)15-5-3-1-2-4(6(5)12)7(13)14/h1-3,12H,(H,13,14)

Upstream product

• 851341-36-1 1-(methoxymethoxy)-2-(trifluoromethoxy)benzene 
• 32858-93-8 2-(trifluoromethoxy)phenol 

Relevant academic research and scientific papers

TRPV1 Antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The site-selective functionalization of halogen-bearing phenols: An exercise in diversity-oriented organometallic synthesis

The organometallic approach to diversity-oriented organic synthesis was subjected to a further test, this time in the phenol series. The model compounds selected were 2,3,6-trifluorophenol, the three isomers of (trifluoromethoxy) phenol and the three isomers of chlorophenol. A combination of optionally site selective metalations and protective group-controlled metalations enabled the selective generation of several isomeric intermediates in each case and their subsequent conversion into functionalized derivatives, in particular hydroxybenzoic acids.